Impact of glycemic control on advanced glycation and inflammation in overweight and obese patients with type 2 diabetes mellitus

Bratislava Medical Journal

Volumn 115, Issue 8, 2014, Pages 457-468

  Kalninova, J ^a   Jakus, V ^a   Glejtkova, M ^b   Kuracka, L ^a   Sandorova, E ^a  

^a Bratislava   (Slovakia)

^b University Hospital in Martin   (Slovakia)

Author keywords

Diabetes mellitus; Glycemic control; Inflammation; Obesity; Overweight

Indexed keywords

EID: 84906966959     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2014_089     Document Type: Article

References (113)

1. Abou-Seif MA, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004; 346: 161-170.
2. Agarwal, N, Chitrika A, Bhattacharjee J, Jain SK. Correlation of tumor necrosis factor-α and interleukin-6 with anthropometric indices of obesity and parameters of insulin resistance in healthy north Indian population. JIACM 2011; 12 (3): 196-204.
3. Ahmad R, Al-Mass A, Atizado V, Al-Hubail A, Al-Ghimlas F, Al-Arouj M, Bennakhi A, Dermine S, Behbehani K. Elevated expression on the toll like receptors 2 and 4 in obese individuals: Its significance for obesity-induced inflammation. J Inflamm (Lond) 2012; 9 (1): e48.
4. Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Al-Abri, S, Al-Lawati, J, Al-Maskari, M. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol 2013; 2013: e976810.
5. Andriankaja OM, Barros SP, Moss K, Panagakos FS, DeVizio W, Beck J, Offenbacher S. Levels of serum interleukin (IL)-6 and gingival cervicular fluid of IL-1 beta and prostaglandin E (2) among non-smoking subjects with gingivitis and type 2 diabetes. J Periodontol 2009; 80 (2): 307-316.
6. Aronson D. Hyperglycemia and pathobiology of diabetic complications. Adv Cardiol 2008; 45: 1-16.
7. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000; 37: 87-92.
8. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000; 58: 684-690.
9. Bansal S, Chawla D, Siddarth M, Banerjee BD, Madhu SV, Tripathi AK. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin Biochem 2013; 46: 109-114.
10. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, Mayas MD, Oliva-Olivera W, Bernal-Lopez MR, El Bekay R, Tinahones FJ. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS ONE 2012; 7 (10): e48155.
11. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2003; 63 (4): 582-592.
12. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.
13. Beaglehole R, Yach D. Globalisation and the prevention and control of non-communicable disease: The neglected chronic disease of adults. Lancet 2003; 362 (9387): 903-908.
14. Boulanger E, Grossin N, Wautier MP, Taamma R, Wautier JL. Mesothelial Rage activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007; 71: 126-133.
15. Boulanger E, Wautier MP, Wautier JL, Boval B, Panis Y, Wernert N, Danze PM, Dequiedt P. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-156.
16. Breslin WL, Johnston CA, Strohacker K, Carpenter KC, Davidson TR, Moreno JP, Foreyt JP, McFarlin BK. Obese Mexican American children have elevated MCP-1, TNF-alpha, monocyte concentration, and dyslipidemia. Pediatrics 2012; 96: E2034-2038.
17. Buc M, Bucova M. Chemokines. Bratisl Lek Listy 2000; 101 (9): 507-511.
18. Bush M, Franke S, Stein G, Wolf G, Collaborative Study Group. Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease? Dtsch Med Wschr 2007; 132: 1810-1814.
19. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K, Esposito K, Jo¨nsson LS, Kolb H, Lansink M, Marcos A, Margioris A, Matusheski N, Nordmann H, O'Brien J, Pugliese G, Rizkalla S, Schalkwijk C, Tuomilehto J, Wa¨rnberg J, Watzl B, Winklhofer-Roob BM. Dietary factors and low-grade inflammation in relation to overweight and obesity. Brit J Nutr 2011; 106 (S3): S1-S78.
20. Cinti S, Mitchel, G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 16 (11): 2347-2355.
21. Czyzewska J, Wasilewska K, Kaminska J, Koper O, Kemona H, Jakubowska, I. Assess the impact of concentrations of inflammatory markers IL-6, CRP in the presence of albuminuria in patients with type 2 diabetes. Pol Merkur Lek 2012; 32 (188): 98-102.
22. DCCT - The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
23. De la Maza MP, Garrido F, Escalante N, Leiva L, Barrera G, Schnitzel S, Zanolli M, Verdaguer J, Hirsch S, Jara N, Bunout D. Fluorescent advanced glycation end-products (ages) detected by spectro-photofluorimetry, as a screening tool to detect diabetic microvascular complications. J Diab Mellitus 2012; 2 (2): 221-226.
24. Doganay S, Everekliuglu C, Er H, Turko¨z Y, Sevinc A, Mehmet N, Savli H. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 2002; 16 (2): 163-170.
25. Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD. Immunologicsl determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 1995; 10 (5): 657-664.
26. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
27. Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis 2013; 19: 1734-1746.
28. Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel Namiduru E. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 2001; 34: 645-650.
29. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
30. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. The Insulin Resistance Atherosclerosis Study: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-1137.
31. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971-1977.
32. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. The West of Scotland Coronary Prevention Study: C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.
33. Brenner H, Koenig W. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-1839.
34. Goh S-Y, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93 (4): 1143-1152.
35. Gottsa¨ter A, Szelag B, Kangro M, Wroblewski M, Sundkvist G. Plasma adiponectin and serum advanced glycated end-products increase and plasma lipid concentrations decrease with increasing duration of type 2 diabetes. Eur J Endocrin 2004; 151: 361-366.
36. Goyal R, Faizy AF, Siddiqui SS, Singhai M. Evaluation of TNF-α and IL-6 levels in obese and non-obese diabetics: pre- and post-insulin effects. North Amer J Med Sci 2012; 4 (4): 180-184.
37. Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y. Role of receptor for advanced glycation end-products and signaling events in advanced glycation end-product -induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant 2006, 21:299-313.
38. Gul A, Rahman MA, Salim A, Simjee SU. Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. J Diab Compl 2009; 23 (5): 343-348.
39. Guzel, S, Seven A, Kocaoglu A, Ilk B, Guzel EC, Saracoglu V, Celebi A. Osteoprotegerin, leptin and IL-6: Association with silent myocardial ischemia in type diabetes mellitus. Diab Vasc Dis Res 2012; 10 (1): 25-31.
40. Hajer GR, van Haeften TW, Visseren FLJ. Adipose tissue dysfunction in obesity, diabetes and vascular disease. Eur Heart J 2008; 29: 2959-2971.
41. Hatfield J. Advanced glycation end-products (AGEs) in hyperglycemic patients. J Young Invest 2005; 19: 1-3.
42. Hegab Y, Gibbons S, Neyses L, Mamas A. Role of advanced glycation end products in cardiovascular disease. World J Cardiol 2012; 4 (4): 90-102.
43. Henle T, Deppisch R, Beck W, Hergesell O, Ha¨nsch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999; 14: 1968-1975.
44. Chen Y-H, Wu G, Wang J-B, Huang G-X Chen X-M. Determination and clinical significance of serum IL-6 and TNF-α in patients with type 2 diabetes mellitus. Chinese J Clin Rehab 20037 (18): 2536-2537.
45. Cheung CM, Vania M, Ang M, Chee SP, Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis 2012; 18: 830-837.
46. Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A "glycoxidation-centric" point of view. Nutr Metab Cardiovasc Dis 2013; 23 (10): 913-919.
47. Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end productsinduced monocyte chemoattractant protein-1 production in microvascular endothelial cells by supressing intracellular reactive oxygen species generation. Diabetologia 2003; 46 (2): 284-287.
48. Kafle D, Singh N, Singh SK, Mandal F, Rimal B. Correlation between hyperglycemia, inflammation and oxidative stress in type-2 diabetic nephropathy subjects. Int J Pharm Biol Arch 2012; 3 (6): 1508-1511.
49. Kalousova´ M, Sˇkrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Phys Res 2002; 51: 597-604.
50. Kalousova´ M, Zima T, Tesarˇ V, Sti´pek S. New markers of advanced damage caused by oxidative and carbonyl stress. Sbor Lek 2001; 102: 465-472.
51. Kalousova´ M, Zima T, Tesarˇ V, Sulkova´ S, Fialova´ L. Relationship between advanced glycoxidation end products, inflammatory markers/ acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney Int 2003; 6, Suppl. 84: S62-S64.
52. Kerkeni M, Saidi A, Bouzidi H, Letaief A, Ben Yahia S Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab. Vasc Dis Res 2012; 10: 239-245.
53. King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol 2008; 79 (8): 1527-1534.
54. Korpa´sˇ J, Jakusˇ J. The expiration reflex fromthe vocal fooˆd. Acta Physiol Hung 2000; 87 (3): 201-215.
55. Laimer M, Ebenbichler CF, Kaser S, Sandhofer A, Weiss H, Nehoda H, Aigner F, Patsch JR. Markers of chronic inflammation and obesity: a prospective study on the reversibility of this association in middle-aged women undergoing weight loss by surgical intervention. Int J Obes Relat Metab Disord 2002; 26: 659-662.
56. Liu J, Shi B, He S, Yao X, Willcox MD, Zhao Z. Changes to tear cytokines of type 2 diabetic patients with or without retinopathy. Mol Vis 2010; 16: 2931-2938.
57. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325 (12): 836-842.
58. Marques-Vidal P, Bastardot F, von Ka¨nel R, Paccaud F, Preisig M, Waeber G Vollenweider P. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (Co-Laus study). Clin Endocrinol 2013; 78 (2): 232-241.
59. Marques-Vidal P, Schmid R, Bochud M, Bastardot F, von Ka¨nel R, Paccaud F, Glaus J, Preisig M, Waeber G, Vollenweider P. Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. The CoLaus study. PLoS ONE 2012; 7 (12): e51768.
60. Miller AD, Nonaka S, Jakusˇ J, Yates BJ. Modulation of vomiting by the medullary midline. Brain Researxch 1996; 737 (1-2): 51-58.
61. Mirza S, Hossain M, Mathews Ch, Martinez P, Pino P, Gay J.L, Rentfro A, McCormick JB, Fisher-Hoch SP. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low lewels of leptin in a population of Mexican Americans: a cross sectional study. Cytokine 2012; 57: 136-142.
62. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002; 45: 805-812.
63. Mu¨nch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669-677.
64. Nass N, Simm A. Advanced glycation end products (AGEs) in diabetes. AHMN Endokrin 2009; 4: 63-75.
65. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 2005; 20: 2601-2604.
66. Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M. Hyperglycemia and glycation in diabetic complications. Antiox Redox Signal 2009; 11: 3071-3109.
67. Nieto-Vasquez I, Verna´ndez-Veledo S, Kra´mer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch Physiol Biochem 2008; 114 (3): 183-194.
68. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-α and insulin sensitivity in elderly men with non-insulin-dependent diabetes melitus. Atheroscler Thromb Vasc Biol 1998; 18: 1199-1202.
69. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 1998; 41: 131-137.
70. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102 (18): 2165-2168.
71. Petrovic MG, Korosec P, Kosnik M, Hawlina M. Vitreous levels of interleukin-8 patients with proliferative diabetic retinopathy. Am J Ophthalmol 2007; 143 (1): 175-176.
72. Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, Nollino L, Cosma C, Fedele D, Lapolla A. Relationship between glyco-oxidation, antioxidant status and microalbuminuria in type 2 diabetic patients. Diabetologia 2009; 52: 1419-1425.
73. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41 (10): 1241-1248.
74. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F, Garancini MP, Ruotolo G, Luzi L, Perseghin G. Association between plasma monocytes chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 2009; 32: 2105-2110.
75. Pitsavos Ch, Tampourlou M, Panagiotakos DB, Skoumas Y, Chrysohoou Ch, Nomikos T, Stefanadis Ch. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from ATTICA study. Rev Diabet Stud 2007; 4: 98-104.
76. Popko K, Gorska E, Stelmaszczyk-Emmel A, Plywaczewski R, Stoklosa A, Gorecka D, Pyrzak B, Demkow U. Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects. Eur J Med Res 2010; 15: 120-122.
77. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
78. Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S. Vitreous and serum levels of plateletderived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res 2009; 34 (2): 152-161.
79. Rapoport MJ, Mor A, Vardi P, Ramot Y, Winker R, Hindi A, Bistritzer T. Decreased secretion of Th2 cytokines precedes up-regulated and delayed secretion of Th1 cytokines in activated peripheral blood mononuclear cells from patients with insulin-dependent diabetes mellitus. J Autoimmun 1998; 11: 635-642.
80. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S64-S73.
81. Ra´cz O, Vi´cha T, Pacˇin J. Glycohemoglobin, glycation of proteins and diabetes mellitus. Martin: Osveta, 1989
82. Rekeneire N, Peila R, Ding J, Colbert LH, Visser M, Shorr RI, Kritchevsky SB, Kuller LH, Strotmeyer ES, Schwartz AV, Vellas B, Harris TB. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 2006; 29 (8): 1902-1908.
83. Sampathkumar R, Balasubramanyam M, Rema M, Premanand C, Mohan V. A novel advanced glycation index and its association with diabetes and microangiopathy. Metabolism 2005; 54 (8): 1002-1007.
84. Sebekova K, Somoza V. Dietary advanced glycation endproducts (AGEs) and their health effects - PRO. Mol Nutr Food Res 2007; 51 (9): 1079-1084.
85. Sharp PS, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 2003; 20 (7): 575-579.
86. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation and products in diabetic nephropathy. Metabolism 2000; 49 (8): 1030-1035.
87. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: Enhanced biological insights. Atherosclerosis 2002; 160 (1): 91-102.
88. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1780.
89. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory presponses. J Clin Invest 2001; 108: 949-955.
90. Simonini A, Moscucci M, Muller DW, Bates ER, Pagani FD, Burdick MD, Strieter RM. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 2000; 101 (13): 1519-1526.
91. Spranger J, Kroke A, Mo¨hlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52 (3): 812-817.
92. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy (in German). Med Klin (Munich) 1995; 90 (3): 134-137.
93. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W, Hanefeld M. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743-749.
94. Tchorzewski H, Glowacka E, Banasik M, Lewkowicz P, Szalapska-Zawodniak M. Activated T lymphocytes from patients with high risk of type I diabetes mellitus have different ability to produce interferon-gamma, interleukin-6 and interleukin-10 and undergo anti-CD95 induced apoptosis after insulin stimulation. Immunol Lett 2001; 75: 225-234.
95. To¨njes A, Fasshauer M, Kratzsch J, Stumvoll M, Blu¨her M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS ONE 2010; 5 (11): e13911.
96. Tsigos C, Kyrou L, Chala E, Tsapogas P, Stavridis JC, Raptis SA, Katsilambros N. Circulating tumour necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 1999; 48 (10): 1332-1335.
97. van den Oever IAM, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm 2010; 2010: e792393.
98. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106 (12): 1439-1441.
99. von Schacky C, Baumann K, Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids 2001; 36: S99-S102.
100. Wagner Z, Wittmann I, Maza´k I, Schnitzel R, Heidland A Kientsch-Engel K, Nagy J. N (epsilon)- (carboxymethyl)lysine levels in patients with type 2 diabetes role of renal function. Am J Kidney Dis 2001; 38 (4): 785-791.
101. Wakabayashi Y, Usui Y, Okunuki Y, Kezuka T, Takeuchi M, Iwasaki T, Ohno A, Goto H. Increases of vitreous monocyte chemotactic protein 1 and interleukin 8 levels in patients with concurrent hypertension and diabetic retinopathy. Retina 2011; 31 (9): 1951-1957.
102. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004; 95: 233-238.
103. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Edocrinol Metab 2001; 280: 685-694.
104. Weisberg SP McCann D, Desai M,Rosenbaum M, Leibel L, Ferrante A. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112 (12): 1796-1808.
105. Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep 2007; 7 (3): 242-248.
106. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277: 20309-20315.
107. Yamamoto Y, Yamamoto H. RAGE-mediated inflammation, type 2 diabetes, and diabetic vascular complication. Front Endocrinol 2013; 4: e105.
108. Yaseen F, Jaleel A, Aftab J, Zuberi A, Alam E. Circulating levels of resistin, IL-6 and lipid profile in elderly patients with ischemic heart disease with and without diabetes. Biomarkers Med 2012; 6 (1): 97-102.
109. Yudkin JS. Inflammation, obesity, and metabolic syndrome. Horm Metab Res 2007; 39 (10): 707-709.
110. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
111. Zahorska-Markiewicz B, Janowska J, Olzanecka-Glinianowicz M, Zurakowski A. Serum concentration of TNF-alpha and soluble TNF-alpha receptors in obesity. Int J Obes Relat Metab Disord 2000; 24: 1392-1395.
112. Zietz B, Scha¨ffler A, Bu¨ttner R, Scho¨lmerich J, Palitzsch KD. Elevated levels of leptin and insulin but not of TNF alpha are associated with hypertension in type 2 diabetic males. Exp Clin Endocrinol Diabetes 2000; 108 (4): 259-264.
113. Zilin S, Naifeng L, Bicheng L, Jiping W. The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin Chim Acta 2001; 313: 69-75.